Literature DB >> 34550540

Patient values and preferences on polypharmacy and deprescribing: a scoping review.

Evan Forest1, Melissa Ireland2, Uma Yakandawala2, Teresa Cavett3, Lalitha Raman-Wilms2, Jamie Falk2, Diana McMillan4, Rhys Linthorst5, Leanne Kosowan3, Lisa Labine3, Christine Leong6.   

Abstract

Background Understanding how patient values and preferences towards polypharmacy and deprescribing have been studied is important to gain insight on current knowledge in this area and to identify knowledge gaps. Aim To describe methods and outcomes for studying patient values and preferences towards polypharmacy and deprescribing, and to identify gaps in the existing literature. Method A scoping review was conducted on English-language studies that examined patient preferences and values related to polypharmacy and/or deprescribing among community-dwelling adults. MEDLINE, Embase, PubMed, PsycINFO, EconLit, Social Science Citation Index, Science Citation Index Expanded, International Pharmaceutical Abstracts, and CINAHL/AgeLine were searched. Results Thirty articles were included. Surveys (n = 17, 56.7%), interviews/focus groups (n = 9, 30.0%), and mixed methods (n = 3, 10.0%), were commonly used methods. Patients Attitudes Towards Deprescribing (PATD) was the most common tool used (n = 9, 30.0%). Twelve themes related to attitudes, social pressure, and control of polypharmacy/deprescribing were identified. The most frequently-encountered themes included desire or willingness to reduce medication load and influence of healthcare provider on medication use. Conclusion PATD was commonly used to assess preferences and values towards polypharmacy and limited knowledge on patient-important outcomes were addressed. Future research should focus on shared decision-making and communicating risk versus benefit of medications.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Deprescribing; Patient preferences; Patient values; Polypharmacy

Mesh:

Year:  2021        PMID: 34550540     DOI: 10.1007/s11096-021-01328-w

Source DB:  PubMed          Journal:  Int J Clin Pharm


  35 in total

1.  The impact of polypharmacy on the health of Canadian seniors.

Authors:  Ben Reason; Michael Terner; Ali Moses McKeag; Brenda Tipper; Greg Webster
Journal:  Fam Pract       Date:  2012-01-05       Impact factor: 2.267

2.  Theory of planned behavior and adherence in chronic illness: a meta-analysis.

Authors:  Antonia Rich; Kim Brandes; Barbara Mullan; Martin S Hagger
Journal:  J Behav Med       Date:  2015-05-21

Review 3.  Clinical consequences of polypharmacy in elderly.

Authors:  Robert L Maher; Joseph Hanlon; Emily R Hajjar
Journal:  Expert Opin Drug Saf       Date:  2013-09-27       Impact factor: 4.250

4.  Factors associated with patient preferences towards deprescribing: a survey of adult patients on prescribed medications.

Authors:  Takuya Aoki; Yosuke Yamamoto; Tatsuyoshi Ikenoue; Shunichi Fukuhara
Journal:  Int J Clin Pharm       Date:  2019-02-05

5.  The multi-dimensional measure of informed choice: a validation study.

Authors:  Susan Michie; Elizabeth Dormandy; Theresa M Marteau
Journal:  Patient Educ Couns       Date:  2002-09

6.  Decision support for patients: values clarification and preference elicitation.

Authors:  Hilary A Llewellyn-Thomas; R Trafford Crump
Journal:  Med Care Res Rev       Date:  2012-11-01       Impact factor: 3.929

Review 7.  Choosing treatment and screening options congruent with values: Do decision aids help? Sub-analysis of a systematic review.

Authors:  Sarah Munro; Dawn Stacey; Krystina B Lewis; Nick Bansback
Journal:  Patient Educ Couns       Date:  2015-11-02

Review 8.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.

Authors:  Denis O'Mahony; David O'Sullivan; Stephen Byrne; Marie Noelle O'Connor; Cristin Ryan; Paul Gallagher
Journal:  Age Ageing       Date:  2014-10-16       Impact factor: 10.668

9.  Rayyan-a web and mobile app for systematic reviews.

Authors:  Mourad Ouzzani; Hossam Hammady; Zbys Fedorowicz; Ahmed Elmagarmid
Journal:  Syst Rev       Date:  2016-12-05

10.  A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial.

Authors:  Philippe Martin; Cara Tannenbaum
Journal:  BMJ Open       Date:  2017-05-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.